Change over period: —
NSE · UNICHEMLAB
UNICHEM LAB
-26.4% from the 52-week high · +68.7% above the low
Unichem Laboratories Ltd. is a pharmaceutical company, which engages in the manufacturing and marketing of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra and currently employs 3,123 full-time employees. The firm is focused on product development, process chemistry and manufacturing complex active pharmaceutical ingredients (API) as well as dosage forms. The company manufactures and markets pharmaceutical formulations as branded generics as well as generics in several markets across the world. The company has several pharma products that address the needs of various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. The firm is also engaged in contract manufacturing with the focus on immediate-release dosage forms, extended-release dosage forms: matrix and pellets, dry powder injections and syrups, novel drug delivery systems, and technology transfer and documentation. Its subsidiaries include Unichem Pharmaceuticals (USA) Inc, Unichem Farmaceutica Do Brasil Lta and Niche Generics Limited UK.
The short version. UNICHEM LAB reported revenue of ₹640 crore for Sep 2026, up 10.5% from a year earlier. Net profit was ₹22 crore. Return on equity was 9.3% in Mar 2026. Promoter holding was 70.22% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
UNICHEM LAB trades 26.4% below its 52-week high and 68.7% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹640 cr.
5.6 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 640 | 633 | 575 | 521 | 579 | 527 | 587 | 533 |
| Net profit | 22 | 41 | 11 | 264 | -12 | -10 | 53 | 58 |
| Net margin % | 3.5 | 6.6 | 1.9 | 50.7 | -2.1 | -2.0 | 9.0 | 10.9 |
| EPS (₹) | 3.16 | 5.89 | 1.55 | 37.54 | -1.69 | -1.49 | 7.52 | 8.22 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2202 | 2111 | 1705 | 1343 | 1270 | 1235 | 1211 | 1180 |
| Net profit | 253 | 138 | -70 | -202 | 33 | 34 | -60 | -24 |
| Net margin % | 11.5 | 6.5 | -4.1 | -15.1 | 2.6 | 2.8 | -5.0 | -2.0 |
| EPS (₹) | 35.91 | 19.53 | -10.01 | -28.72 | 4.7 | 4.88 | -8.55 | -3.38 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 9.3% in Mar 2026; debt to equity is 0.17.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 9.3 | 5.6 | -3.0 | -8.3 |
| Return on capital % | 11.4 | 6.8 | -1.6 | -6.2 |
| EBITDA margin % | 19.8 | 14.0 | 4.3 | -3.3 |
| Net margin % | 11.2 | 6.4 | -4.1 | -14.6 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 17.9% | 12.0% |
| Profit CAGR | — | 49.1% |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Up 1.64 pts over 8 quarters.
Down 2.23 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 70.22 | 70.22 | 70.22 | 70.22 | 70.22 | 70.22 | 70.22 | 70.22 | 0.0 |
| FII | 1.06 | 0.98 | 0.98 | 1.0 | 0.99 | 1.0 | 0.9 | 2.7 | +1.64 |
| DII | 11.63 | 11.32 | 10.92 | 10.75 | 10.74 | 10.63 | 10.46 | 9.4 | -2.23 |
| Public | 17.09 | 17.48 | 17.88 | 18.03 | 18.05 | 18.15 | 18.42 | 17.68 | +0.59 |
Mutual fund holdings · Oct 2026
4 schemes hold this stock
4 the month before.
- DSP Healthcare Fund1.47% of NAV
- HDFC Small Cap Fund0.62% of NAV
- Motilal Oswal BSE Healthcare ETF0.06% of NAV
- Bandhan BSE Healthcare Index Fund0.06% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for UNICHEM LAB are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about UNICHEM LAB
What is the UNICHEM LAB share price?
UNICHEM LAB (UNICHEMLAB) last closed at ₹479.20, up 0.02% on the day. Its 52-week range is ₹284.05 to ₹650.60.
What is the market cap of UNICHEM LAB?
UNICHEM LAB has a market capitalisation of about ₹3,401 crore. Its price-to-earnings ratio is 9.8.
How are UNICHEM LAB's latest results?
UNICHEM LAB reported revenue of ₹640 crore for Sep 2026, up 10.5% from a year earlier. Net profit was ₹22 crore. Return on equity was 9.3% in Mar 2026. Promoter holding was 70.22% in Sep 2026, up 0.00 points over 8 quarters.
Who owns UNICHEM LAB?
As of Sep 2026, shareholding was: Promoter 70.22%, FII 2.7%, DII 9.4%, Public 17.68%.
How many mutual funds hold UNICHEM LAB?
4 mutual fund schemes held UNICHEM LAB in October 2026. That compares with 4 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 01 Aug 2022 · Final Dividend - Rs. 4
- 22 Jul 2021 · Final Dividend - Rs. 4
- 20 Aug 2020 · Dividend - Rs. 4
- 18 Jul 2019 · Dividend - Rs. 4
- 19 Jul 2018 · Dividend - Rs. 5
- 13 Jul 2017 · Final Dividend - Rs. 3
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.